Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

Vinod K. Rustgia Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA;b Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USACorrespondence[email protected]

https://orcid.org/0000-0002-4105-5783

Steve B. Duffc Veritas Health Economics Consulting, Inc, Carlsbad, CA, USA

https://orcid.org/0000-0002-0506-2900

Mohamed I. Elsaida Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA;d Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA

https://orcid.org/0000-0001-7963-2438

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Jai Kumar, Sana Mohsin, Misha Hasan, Abdur Raheem Bilal, Kumail Mustafa Ali, Ahmed Umer, Dua Zehra Mohammad Hadi, Sanjna Nandlal & Sarwan Kumar. (2024) Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 48:1, pages 102261.
Crossref

Peter Gal, Gyorgyi Feldmajer, Margarida Augusto, Ray Gani, Emma Hook, Ash Bullement, Zoe Philips & Inger Smith. (2023) De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation. PharmacoEconomics 41:12, pages 1629-1639.
Crossref

Elisa Barrón-Cabrera, Raúl Soria-Rodríguez, Fernando Amador-Lara & Erika Martínez-López. (2023) Physical Activity Protocols in Non-Alcoholic Fatty Liver Disease Management: A Systematic Review of Randomized Clinical Trials and Animal Models. Healthcare 11:14, pages 1992.
Crossref

Roberta Forlano, Giordano Sigon, Benjamin H. Mullish, Michael Yee & Pinelopi Manousou. (2023) Screening for NAFLD—Current Knowledge and Challenges. Metabolites 13:4, pages 536.
Crossref

Mehdi Javanbakht, Jesse Fishman, Eoin Moloney, Peter Rydqvist & Amir Ansaripour. (2022) Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics - Open 7:1, pages 93-110.
Crossref

Mohamed I. Elsaid, You Li, John F. P. Bridges, Guy Brock, Carlos D. Minacapelli & Vinod K. Rustgi. (2022) Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. JAMA Network Open 5:10, pages e2235003.
Crossref

Iman M. Attia. (2022) Log-Linear Model and Multistate Model to Assess the Rate of Fibrosis in Patients With NAFLD. Frontiers in Applied Mathematics and Statistics 8.
Crossref

Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date